FDA approves Vyvanse for binge-eating disorder

FDA approved an sNDA under Priority Review for Vyvanse lisdexamfetamine dimesylate ( S-877489) from Shire plc (LSE:SHP; NASDAQ:SHPG) to treat binge-eating disorder in adults. The agency said Vyvanse is the only FDA-approved treatment for this indication.

Vyvanse, Shire's top-selling drug, is approved to treat ADHD in the U.S., Canada and Australia. Sales of the prodrug of amphetamine were $1.1 billion over the nine months ended Sept. 30, 2014. ...